Phase 3 NSCLC (Non-small Cell Lung Cancer) Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer)
Revolution Medicines, Inc.420 enrolled129 locationsNCT06881784
Recruiting
Phase 3
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital70 enrolled1 locationNCT07016126
Recruiting
Phase 3
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
NSCLC (Non-small Cell Lung Cancer)
Akeso560 enrolled1 locationNCT06617416